Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 177Lu-EVS459 |
Synonyms | |
Therapy Description |
177Lu-EVS459 is a radioconjugate comprising the radionuclide Lutetium-177 linked to EVS459, a FOLR1-targeting ligand, which delivers radiation to FOLR1-expressing tumor cells, potentially resulting in tumor cell death (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
177Lu-EVS459 | [177Lu]Lu-EVS459|Lutetium Lu 177 EVS459 | 177Lu-EVS459 is a radioconjugate comprising the radionuclide Lutetium-177 linked to EVS459, a FOLR1-targeting ligand, which delivers radiation to FOLR1-expressing tumor cells, potentially resulting in tumor cell death (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06376253 | Phase I | 177Lu-EVS459 | A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers | Recruiting | ISR | 0 |